Skip to main content
WAKAMOTO PHARMACEUTICAL CO.,LTD. logo

WAKAMOTO PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 4512 ISIN · JP3991200001 T Manufacturing
Open in API
Filings indexed 59 across all filing types
Latest filing 2023-11-13 Report Publication Anno…
Country JP Japan
Listing T 4512

About WAKAMOTO PHARMACEUTICAL CO.,LTD.

https://www.wakamoto-pharm.co.jp/englis…

WAKAMOTO PHARMACEUTICAL CO., LTD. is a company engaged in the research, development, production, and sale of pharmaceuticals. Its business encompasses both ethical (prescription) drugs and over-the-counter (OTC) products, as well as medical devices and health foods. The company specializes in therapeutic areas such as gastroenterology and is known as a pioneer in self-medication, with its flagship product being the nutrient-rich gastrointestinal remedy, "WAKAMOTO". The company actively manages a drug pipeline and engages in clinical trials to bring new therapeutic solutions to market.

Recent filings

Filing Released Lang Actions
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically accompanying a Second Quarter Report (Interim Report). While it references the quarterly report, the document itself is a formal regulatory filing confirming the accuracy of the financial statements. Given the specific nature of this regulatory confirmation filing, it falls under the RNS (Regulatory Filings) category as it is a mandatory regulatory disclosure that does not constitute the full financial report itself.
2023-11-13 Japanese
四半期報告書－第129期第2四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Wakamoto Pharmaceutical Co., Ltd., covering the second quarter of the 129th fiscal period (April 1, 2023, to September 30, 2023). It contains detailed financial statements, including the balance sheet, and is filed in accordance with the Financial Instruments and Exchange Act of Japan. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. H1 2024
2023-11-13 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically accompanying a Quarterly Report (Dai-ichi shihanki hokokusho). While it references a quarterly report, the document itself is a formal regulatory filing confirming the accuracy of the report's contents. Given the specific nature of this regulatory confirmation filing, it falls under the general regulatory filings category.
2023-08-10 Japanese
四半期報告書－第129期第1四半期(2023/04/01－2023/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (第１四半期報告書) for Wakamoto Pharmaceutical Co., Ltd. for the period ending June 30, 2023. It contains detailed financial statements, including the balance sheet, income statement, and segment information, as required by the Financial Instruments and Exchange Act of Japan. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2024
2023-08-10 Japanese
内部統制報告書－第128期(2022/04/01－2023/03/31)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act in Japan. This type of report is a mandatory regulatory filing that assesses the effectiveness of a company's internal controls over financial reporting. Since it is a specific regulatory requirement and does not fit into the other categories like 10-K (Annual Report) or AR (Audit Report), it is best classified as a Regulatory Filing.
2023-06-28 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under Article 24-4-2 of the Financial Instruments and Exchange Act of Japan. This is a mandatory document filed alongside the Annual Securities Report (Yuuka Shouken Houkokusho) to confirm the accuracy of the report's contents. Since it is a regulatory filing required by the Financial Services Agency (Kanto Local Finance Bureau) and does not fit into the specific categories like 10-K or AR, it is classified as a Regulatory Filing (RNS). FY 2023
2023-06-28 Japanese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.